EP1171579A4 - Human tumor necrosis factor receptor tr9 - Google Patents

Human tumor necrosis factor receptor tr9

Info

Publication number
EP1171579A4
EP1171579A4 EP00914975A EP00914975A EP1171579A4 EP 1171579 A4 EP1171579 A4 EP 1171579A4 EP 00914975 A EP00914975 A EP 00914975A EP 00914975 A EP00914975 A EP 00914975A EP 1171579 A4 EP1171579 A4 EP 1171579A4
Authority
EP
European Patent Office
Prior art keywords
necrosis factor
tumor necrosis
factor receptor
human tumor
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00914975A
Other languages
German (de)
French (fr)
Other versions
EP1171579A1 (en
Inventor
Jian Ni
Reiner L Gentz
Guo-Liang Yu
Ping Fan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1171579A1 publication Critical patent/EP1171579A1/en
Publication of EP1171579A4 publication Critical patent/EP1171579A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
EP00914975A 1999-03-24 2000-03-16 Human tumor necrosis factor receptor tr9 Withdrawn EP1171579A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12601999P 1999-03-24 1999-03-24
US126019P 1999-03-24
US13422099P 1999-05-14 1999-05-14
US134220P 1999-05-14
PCT/US2000/006831 WO2000056862A1 (en) 1999-03-24 2000-03-16 Human tumor necrosis factor receptor tr9

Publications (2)

Publication Number Publication Date
EP1171579A1 EP1171579A1 (en) 2002-01-16
EP1171579A4 true EP1171579A4 (en) 2002-07-31

Family

ID=26824194

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00914975A Withdrawn EP1171579A4 (en) 1999-03-24 2000-03-16 Human tumor necrosis factor receptor tr9

Country Status (5)

Country Link
EP (1) EP1171579A4 (en)
JP (1) JP2002542771A (en)
AU (1) AU3628800A (en)
CA (1) CA2365255A1 (en)
WO (1) WO2000056862A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503963A (en) * 1997-06-11 2002-02-05 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Human tumor necrosis factor receptor TR9
AU2001257008A1 (en) * 2000-05-10 2001-11-20 Eli Lilly And Company Treating t-cell mediated diseases by modulating dr6 activity
WO2003013585A1 (en) * 2001-08-08 2003-02-20 Genset S.A. Mifaxin agonists and antagonists for use in the treatment of metabolic
AU2002334161B2 (en) * 2001-10-13 2007-03-29 Asterion Limited Chimeric glycosylphosphatidylinositol containing peptides
EP1455825A4 (en) * 2001-12-17 2006-05-31 Lilly Co Eli Treating b-cell mediated diseases by modulating dr6 activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056892A1 (en) * 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114417A0 (en) * 1994-07-07 1995-10-31 Res Dev Foundation Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
US5563039A (en) * 1995-03-31 1996-10-08 Tularik, Inc. TNF receptor-associated intracellular signaling proteins and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056892A1 (en) * 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 9 September 1998 (1998-09-09), PAN ET AL.: "Homosapiens TNFR-related death receptor-6 (DR6) mRNA, complete cds", XP002144008, Database accession no. AF068868 *
PAN G ET AL: "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 431, 1998, pages 351 - 356, XP002113408, ISSN: 0014-5793 *
See also references of WO0056862A1 *

Also Published As

Publication number Publication date
WO2000056862A1 (en) 2000-09-28
EP1171579A1 (en) 2002-01-16
AU3628800A (en) 2000-10-09
CA2365255A1 (en) 2000-09-28
JP2002542771A (en) 2002-12-17

Similar Documents

Publication Publication Date Title
EP0988371A4 (en) Human tumor necrosis factor receptor tr9
HK1200316A1 (en) Therapeutic microfoams
EP1224274A4 (en) Tumor necrosis factor related receptor, tr6
IL148496A0 (en) Therapeutic quinazoline derivatives
AU7705198A (en) Human tumor necrosis factor receptor tr10
ZA952587B (en) Human tumor necrosis factor receptor
GB9930570D0 (en) Therapy
GB9907243D0 (en) Therapy
AU3766700A (en) Human tumor necrosis factor receptor-like 2
GB9911802D0 (en) Therapeutic combination
GB9911803D0 (en) Therapeutic combination
GB9911804D0 (en) Therapeutic combination
EP1171579A4 (en) Human tumor necrosis factor receptor tr9
EP1191940A4 (en) Tumor necrosis factor receptor 5
IL143990A0 (en) Bone stimulating factor
EP1210370A4 (en) Human tumor necrosis factor receptor tr16
EP1194439A4 (en) Human eag2
GB9810920D0 (en) Therapeutic use
EP1158856A4 (en) Human fas
GB9911238D0 (en) Therapeutic use
GB9811624D0 (en) Therapeutic use
TW384889U (en) Combination truss
AU141196S (en) Tissue
TW387258U (en) Medical air-sucker
GB9912184D0 (en) Therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020617

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030826

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060306